FR08C0013I2 - Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer - Google Patents

Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Info

Publication number
FR08C0013I2
FR08C0013I2 FR08C0013C FR08C0013C FR08C0013I2 FR 08C0013 I2 FR08C0013 I2 FR 08C0013I2 FR 08C0013 C FR08C0013 C FR 08C0013C FR 08C0013 C FR08C0013 C FR 08C0013C FR 08C0013 I2 FR08C0013 I2 FR 08C0013I2
Authority
FR
France
Prior art keywords
dexamethasone
combination therapy
treat cancer
cancer
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0013C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of FR08C0013I1 publication Critical patent/FR08C0013I1/fr
Application granted granted Critical
Publication of FR08C0013I2 publication Critical patent/FR08C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR08C0013C 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer Active FR08C0013I2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
EP00927584A EP1176964B8 (en) 1999-05-13 2000-05-15 Uses of et743 for treating cancer

Publications (2)

Publication Number Publication Date
FR08C0013I1 FR08C0013I1 (https=) 2008-05-30
FR08C0013I2 true FR08C0013I2 (fr) 2009-10-30

Family

ID=27546594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0013C Active FR08C0013I2 (fr) 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Country Status (32)

Country Link
US (1) US8119638B2 (https=)
EP (3) EP1702618B1 (https=)
JP (2) JP2002544231A (https=)
KR (1) KR20020019914A (https=)
CN (2) CN100477993C (https=)
AR (1) AR028476A1 (https=)
AT (3) ATE375795T1 (https=)
AU (2) AU777417B2 (https=)
BG (1) BG65680B1 (https=)
BR (1) BR0010531A (https=)
CA (1) CA2373794C (https=)
CY (4) CY1105818T1 (https=)
CZ (1) CZ301482B6 (https=)
DE (4) DE60045720D1 (https=)
DK (3) DK1702618T3 (https=)
ES (2) ES2294756T3 (https=)
FR (1) FR08C0013I2 (https=)
HU (2) HU229866B1 (https=)
IL (2) IL146434A0 (https=)
LU (1) LU91418I2 (https=)
MX (1) MXPA01011562A (https=)
MY (1) MY164077A (https=)
NL (1) NL300337I2 (https=)
NO (2) NO324564B1 (https=)
NZ (1) NZ515423A (https=)
PL (1) PL198185B1 (https=)
PT (3) PT1702618E (https=)
SI (3) SI1176964T1 (https=)
SK (1) SK287580B6 (https=)
TR (1) TR200103819T2 (https=)
UA (1) UA74782C2 (https=)
WO (1) WO2000069441A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
CA3011527A1 (en) * 2016-02-04 2017-08-10 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
EP4353232A3 (en) 2020-04-15 2024-06-26 EVER Valinject GmbH Composition comprising trabectedin and an amino acid
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ATE493983T1 (de) * 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en) * 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
BR0115162A (pt) 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002078678A2 (en) 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
KR20020019914A (ko) 2002-03-13
LU91418I2 (fr) 2008-05-13
EP1702618A3 (en) 2006-12-27
HU229866B1 (en) 2014-10-28
TR200103819T2 (tr) 2002-04-22
ES2294756T3 (es) 2008-04-01
EP1716853A2 (en) 2006-11-02
DE60030554T2 (de) 2007-09-13
AU2005200180B2 (en) 2007-12-13
CY1107143T1 (el) 2010-07-28
DK1716853T3 (da) 2011-06-27
EP1716853B9 (en) 2011-09-28
CN1679631A (zh) 2005-10-12
NO20015516D0 (no) 2001-11-12
WO2000069441A1 (en) 2000-11-23
EP1716853B1 (en) 2011-03-09
EP1176964B1 (en) 2006-09-06
EP1176964A1 (en) 2002-02-06
AR028476A1 (es) 2003-05-14
AU2005200180B9 (en) 2008-05-29
BR0010531A (pt) 2002-06-04
EP1176964B8 (en) 2007-10-10
US8119638B2 (en) 2012-02-21
CY2008007I2 (el) 2009-11-04
DK1702618T3 (da) 2008-02-25
SI1176964T1 (sl) 2007-02-28
PT1176964E (pt) 2007-01-31
NZ515423A (en) 2004-04-30
IL146434A0 (en) 2002-07-25
SI1716853T1 (sl) 2011-10-28
CY1105818T1 (el) 2011-02-02
JP2002544231A (ja) 2002-12-24
JP5777562B2 (ja) 2015-09-09
FR08C0013I1 (https=) 2008-05-30
EP1716853A3 (en) 2006-11-15
CA2373794C (en) 2005-10-11
NL300337I2 (nl) 2008-09-01
JP2012149095A (ja) 2012-08-09
PL352931A1 (en) 2003-09-22
DE60045720D1 (de) 2011-04-21
NO324564B1 (no) 2007-11-19
AU777417B2 (en) 2004-10-14
MY164077A (en) 2017-11-30
CN100477993C (zh) 2009-04-15
NL300337I1 (nl) 2008-05-01
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
UA74782C2 (uk) 2006-02-15
NO2008005I2 (https=) 2010-09-27
IL146434A (en) 2008-03-20
CZ301482B6 (cs) 2010-03-17
DK1176964T3 (da) 2007-01-15
DE60036826T2 (de) 2008-08-28
SI1702618T1 (sl) 2008-02-29
PT1702618E (pt) 2008-01-11
CN1360503A (zh) 2002-07-24
CZ20014081A3 (cs) 2002-11-13
NO20015516L (no) 2002-01-11
ATE500830T1 (de) 2011-03-15
PT1716853E (pt) 2011-05-12
NO2008005I1 (no) 2008-06-09
EP1702618B1 (en) 2007-10-17
MXPA01011562A (es) 2002-07-30
SK287580B6 (sk) 2011-03-04
EP1702618A2 (en) 2006-09-20
DE122008000013I1 (de) 2008-08-07
DE60030554T8 (de) 2008-01-10
HUP0201187A2 (en) 2002-09-28
DE60036826D1 (de) 2007-11-29
CY2008007I1 (el) 2009-11-04
CA2373794A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
US20070275942A1 (en) 2007-11-29
SK16442001A3 (sk) 2002-03-05
HUS1500001I1 (hu) 2016-08-29
CY1112753T1 (el) 2016-02-10
ATE375795T1 (de) 2007-11-15
ATE338552T1 (de) 2006-09-15
PL198185B1 (pl) 2008-06-30
BG65680B1 (bg) 2009-06-30
AU4597500A (en) 2000-12-05
HUP0201187A3 (en) 2002-11-28
LU91418I9 (https=) 2019-01-02
ES2272279T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
EP1535610A4 (en) THERAPEUTIC CANCER
PT1147114E (pt) Novos aralquilaminas de espirofuropiridinas uteis em terapia.
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
DE60020327D1 (de) Wasserbehandlungsvorrichtung
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
FI20020071A7 (fi) Applikaattori kõytettõvõksi refleksoterapiassa
FI20020072A7 (fi) Applikaattori kõytettõvõksi refleksoterapiassa
IL147748A0 (en) Use of etodolac to treat cancer
GB9912159D0 (en) Improvements in and relating to the treatment of water
NO20014725D0 (no) Forbedret kreftbehandling med temozolomid
IS6576A (is) Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
EP1242071A4 (en) USE OF PARTHENOLIDE TO INHIBIT CANCER
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
ZA200110436B (en) Therapeutic use of melatonin.
ATE302165T1 (de) Wasserbehandlung
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
FR2797183B1 (fr) Installation de massage pour le corps humain
HUP0105203A3 (en) S-nitrosothiols as agents for the treatment of circulatory dysfunctions and their use
GB9911238D0 (en) Therapeutic use
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
FI20002612A0 (fi) Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
GB9905300D0 (en) Therapy and use of agents in therapy
GB9905307D0 (en) Therapy and use of compounds in therapy